About Us
Draft Therapeutic Goods (Federal Inspectors, Federal Government Analysts and Federal Quality Control Laboratories) Rules, 2026 (11.11.2026)
Clarification Regarding 1688(I)/2026 dated 6,Oct 2026
Directive Regarding Mandatory Printing of Disclaimer on the Labels of Formula Milk Products Intended for Infants and Young Children Aged 1 to 36 Months
S.R.O. 1915(I)/2026, Notification of Amendments in the Drugs (Research) Rules 1978 (28.10.2026)
Development of Medical Devices Module on PSW
Notification of Health and OTC Products as Therapeutic Goods
Compliance of 2D Barcoding and Serialization (Track & Trace System) for all Manufactured and Imported Pharmaceutical Products w.e.f. 9th October, 2026
S.R.O. 1660(I)/2026 (Revised DRAP Regulatory Fee for Therapeutic Goods)
Notification of Draft Amendments in the Drugs (Research) Rules, 1978
The comments of stakeholders are invited on the proposed amendments in the Drugs (Research) Rules, 1978. Comments or suggestions may be forwarded to the Drug Regulatory Authority of Pakistan for consideration within seven days of the publication of the notification, either by post or by email at director.legal∂dra.gov.pk
